Iron and hepatitis C: Beginning to make sense

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 11, 2007, Pages 1703-1704

  Bassett, Mark L ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; IRON; RIBAVIRIN;

DISEASE ASSOCIATION; EDITORIAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLAMMATION; IRON BLOOD LEVEL; IRON OVERLOAD; LIVER BIOPSY; LIVER SURGERY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATHOGENESIS; PATIENT CARE; PHLEBOTOMY; PRIORITY JOURNAL;

EID: 34948857529     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05106.x     Document Type: Editorial

References (16)

1. Fujita N, Sugimoto R, Urawa N et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J Gastroenterol. Hepatol. 2007 22 : 1886 93.
2. Deugnier YM, Loreal O, Turlin B et al. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their biochemical correlations. Gastroenterology 1992 102 : 2050 9.
3. Guyader D, Thirouard AS, Erdtmann L et al. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J. Hepatol. 2007 46 : 587 95.
4. Carlo C, Daniela P, Giancarlo C. Iron depletion and response to interferon in chronic hepatitis C. Hepatogastrenterol 2003 50 : 1467 71.
5. Kawamura Y, Akuta N, Sezeki H et al. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J. Gastroenterol. 2005 40 : 901 6.
6. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004 53 : 451 5.
7. Bonkovsky HL, Troy N, McNeal K et al. Iron and HFE or TR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J. Hepatol. 2002 37 : 848 54.
8. Geier A, Reugels M, Weiskirchen R et al. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. Liver Int. 2004 24 : 285 94.
9. Lebray P, Zylberberg H, Hue S et al. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J. Viral Hepat. 2004 11 : 175 82.
10. Tung BY, Emond KJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003 124 : 318 26.
11. Bonkovsky HL, Naishadham D, Lambrecht RW et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006 131 : 1440 51.
12. Pianko S, McHutchison JG, Gordon SC et al. Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. J. Interferon Cytokine Res. 2002 22 : 483 9.
13. Hofer H, Osterreicher C, Jessner W et al. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J. Hepatol. 2004 40 : 1018 22.
14. Rulyak SJ, Eng SC, Patel K, McHutchison JG, Gordon SC, Kowdley KV. Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am. J. Gastroenterol. 2005 100 : 332 7.
15. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J. Hepatol. 2002 36 : 687 91.
16. Olynyk JK, Reddy KR, Di Bisceglie AM et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995 108 : 1104 9.